2026-10-04
Propanc Biopharma clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 31,076 +0.87%
S&P 7,774 +0.66%
GOLD $4,196 +0.95%
BTC $86,174 +0.45%
VIX 15.31 −1.35%
live tape · as of 13:01 UTC
The Screen · Healthcare · Biotechnology
Propanc Biopharma Inc
PPCB · NASDAQ · USD · Market cap $3M · 1 employees
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia.
Not yet scored0.61 USD
Screen close, 2025-06-30 · not a live quote
Last reviewed 463 days ago
Screened 2025-06-30 · the tape above runs as of 13:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 0.61 against the desk's fair-value range, over the last year.
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price0.61 USD
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown0.61+0.0% to today
2026-09-09Read Markup1.49-59.1% to today
2026-07-02Read Markdown2.27-73.1% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markdown label.
Propanc Biopharma Inc holds its Markdown at $0.61. The statistical read favours the sellers, held for 86 days.
| Phase | Markdown · caution |
| Quantitative state | The statistical read favours the sellers, held for 86 days |
| Price at the screen | $0.61 |
| Valuation | 0.00 trailing · N/A forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 3.30 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Propanc Biopharma clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
We do not yet have the financial statements needed to run the debt, cash, receivables and income screens for Propanc Biopharma, so it is not scored yet.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
The Business, in Plain Words| Trailing P/E | 0.0x |
| EPS, trailing | 570.50 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -127.0%not currently earning a positive return on equity |
| FCF yield | 140.74% |
| Debt to equity | 0.05minimal debt: a conservative balance sheet |
| Current ratio | 2.37comfortably covers its short-term bills |
| Beta | 3.30much more volatile than the market |
| Short interest, float | 0.01% |
| 52-week range | 1.30 - 270.25 |
| Moat | NONE |
| Market cap | $3M |
| Employees | 1 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; its business and earnings are exposed to Australia and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradePPCB trades on NASDAQ (the company is based in Australia). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-02
Markdown · changed $0.61
-59.1% Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 59.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 7%.
2026-09-09
Markup · changed $1.49
+0.0% Entry 5
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 7%.
2026-08-09
Markdown $1.49
-34.4% Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 34.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 7%.
2026-07-18
Markdown $2.27
+0.0% Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 7%.
2026-07-03
Markdown $2.27
+0.0% Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02
Markdown $2.27
Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
AZTRAzitra, Inc.
XRTXXORTX Therapeutics Inc
LABTLakewood-Amedex Biotherapeutics Inc
VRAXVirax Biolabs Group Ltd
ADTXAditxt Inc
DCOYDecoy Therapeutics Inc
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $2.35 | -42.2% | · | $578 | -42.2% |
| 2 months | $2.58 | -47.2% | · | $528 | -47.2% |
| 3 months | $3.03 | -55.0% | · | $450 | -55.0% |
| 6 months | $20.17 | -93.3% | · | $68 | -93.3% |
| 1 year | $200.00 | -99.3% | · | $7 | -99.3% |
| 2 years | $0.08 | +1,600.5% | · | $17,005 | +1,600.5% |
| 3 years | $2.50 | -45.6% | · | $544 | -45.6% |
| 5 years | $3,150.00 | -100.0% | · | $0 | -100.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever PPCB does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.